Did Thermo Fisher raise or change its 2025 guidance?

This 8-K does not include updated 2025 guidance. The company said it would provide updated guidance during its earnings conference call on October 22, 2025 at 8:30 a.m. ET, so the guidance itself must be taken from the call or related materials.

Why did adjusted EPS grow 10% while GAAP EPS was flat?

Adjusted EPS excludes items such as amortization of acquisition-related intangibles ($435 million in the quarter, about $1.15 per share), restructuring and other costs ($135 million, about $0.36 per share), and acquisition-related adjustments. Restructuring costs rose from $45 million a year earlier, and GAAP net income attributable to the company was $1.62 billion versus $1.63 billion.

How healthy is the company's cash generation right now?

Operating cash flow in Q3 was $2.24 billion, but capital expenditures rose to $404 million, which reduced free cash flow to $1.84 billion. Year to date, operating cash flow fell to $4.36 billion from $5.38 billion, and free cash flow fell to $3.32 billion from $4.50 billion, largely due to a larger working-capital outflow of $2.26 billion.

How did the company's balance sheet change during 2025?

Total debt rose to roughly $35.7 billion (short-term $3.82 billion plus long-term $31.86 billion) from roughly $31.3 billion at year-end 2024, partly to fund $4.04 billion of acquisitions and $2.96 billion of share repurchases over nine months. Cash and equivalents fell to $1.98 billion from $4.01 billion, and goodwill increased to $49.29 billion.

What drove the difference in organic growth between the quarter and the year to date?

Organic growth was 3% in the third quarter but 2% for the first nine months, while reported revenue growth was 5% for the quarter and 3% year to date. Acquisitions contributed about 1 point in the quarter and essentially nothing year to date, and currency contributed about 1 point in the quarter and nothing year to date.

TMO 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 22, 2025. Cited figures are marked; the original filing is the authoritative source.

Thermo Fisher Scientific (TMO) reported third quarter 2025 results for the fiscal quarter ended September 27, 2025.

Revenue rose 5% year over year to $11.12 billion^a, with organic growth of 3%; acquisitions contributed about 1 point and currency about 1 point. GAAP diluted EPS was $4.27, essentially flat versus $4.25 a year earlier, while adjusted EPS grew 10% to $5.79. Adjusted operating margin expanded to 23.3% from 22.3%, while GAAP operating margin held roughly steady at 17.4% versus 17.3%.

The gap between GAAP and adjusted results is driven mainly by amortization of acquisition intangibles ($435 million^b) and higher restructuring costs ($135 million versus $45 million). Cash generation and capital deployment were the other focus areas. Free cash flow was $1.84 billion, down from $1.92 billion, as capital expenditures rose to $404 million from $271 million.

Over the first nine months, free cash flow fell to $3.32 billion^c from $4.50 billion, and organic growth for that period was 2%. During the quarter the company completed the acquisitions of Solventum's Filtration and Separation business and Sanofi's Ridgefield, New Jersey fill-finish site, and it repurchased $1.0 billion of stock. Total debt rose: short-term obligations were $3.82 billion and long-term obligations were $31.86 billion at quarter-end, compared with $2.21 billion and $29.06 billion at year-end 2024.

Cash and equivalents fell to $1.98 billion^d from $4.01 billion. The company did not include updated 2025 guidance in the filing; management said it would provide it on the earnings call at 8:30 a.m.

ET on October 22, 2025. Investors should therefore treat the guidance update, which is not contained in this 8-K, as the key forward-looking element to review alongside these results.

02—Key points

Key Highlights

Q3 2025 revenue grew 5% to $11.12 billion (organic growth 3%, acquisitions about 1 point, currency about 1 point).
GAAP diluted EPS was $4.27, flat versus $4.25; adjusted EPS grew 10% to $5.79 versus $5.28.
Adjusted operating margin expanded 100 basis points to 23.3%, while GAAP operating margin was roughly flat at 17.4%.
Free cash flow was $1.84 billion in Q3, down from $1.92 billion, and $3.32 billion year to date versus $4.50 billion a year earlier.
Capital deployment included completing the Solventum Filtration and Separation and Sanofi Ridgefield acquisitions and repurchasing $1.0 billion of stock.
Total debt increased to about $35.7 billion from about $31.3 billion at year-end 2024, and cash fell to $1.98 billion.
Updated 2025 financial guidance was not included in the 8-K and will be provided on the October 22, 2025 earnings call.

03—Questions

Frequently Asked Questions

Did Thermo Fisher raise or change its 2025 guidance?
This 8-K does not include updated 2025 guidance. The company said it would provide updated guidance during its earnings conference call on October 22, 2025 at 8:30 a.m. ET, so the guidance itself must be taken from the call or related materials.
Why did adjusted EPS grow 10% while GAAP EPS was flat?
Adjusted EPS excludes items such as amortization of acquisition-related intangibles ($435 million in the quarter, about $1.15 per share), restructuring and other costs ($135 million, about $0.36 per share), and acquisition-related adjustments. Restructuring costs rose from $45 million a year earlier, and GAAP net income attributable to the company was $1.62 billion versus $1.63 billion.
How healthy is the company's cash generation right now?
Operating cash flow in Q3 was $2.24 billion, but capital expenditures rose to $404 million, which reduced free cash flow to $1.84 billion. Year to date, operating cash flow fell to $4.36 billion from $5.38 billion, and free cash flow fell to $3.32 billion from $4.50 billion, largely due to a larger working-capital outflow of $2.26 billion.
How did the company's balance sheet change during 2025?
Total debt rose to roughly $35.7 billion (short-term $3.82 billion plus long-term $31.86 billion) from roughly $31.3 billion at year-end 2024, partly to fund $4.04 billion of acquisitions and $2.96 billion of share repurchases over nine months. Cash and equivalents fell to $1.98 billion from $4.01 billion, and goodwill increased to $49.29 billion.
What drove the difference in organic growth between the quarter and the year to date?
Organic growth was 3% in the third quarter but 2% for the first nine months, while reported revenue growth was 5% for the quarter and 3% year to date. Acquisitions contributed about 1 point in the quarter and essentially nothing year to date, and currency contributed about 1 point in the quarter and nothing year to date.

04—Continue

← View all 8-K filings